Plasminogen activator inhibitor-1 4G/5G and the MTHFR 677C/T polymorphisms and susceptibility to polycystic ovary syndrome

A meta-analysis

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

The aim of this study was to explore whether the plasminogen activator inhibitor-1 (PAI-1) 4G/5G and the methylenetetrahydrofolate reductase (MTHFR) 677C/T polymorphisms are associated with susceptibility to polycystic ovary syndrome (PCOS). Meta-analyses were conducted to determine the association between the PAI-1 4G/5G and MTHFR 677C/T polymorphisms and PCOS using: (1) allele contrast (2) homozygote contrast, (3) recessive, and (4) dominant models. For meta-analysis, nine studies of the PAI-1 4G/5G polymorphism with 2384 subjects (PCOS, 1615; controls, 769) and eight studies of the MTHFR 677C/T polymorphism with 1270 study subjects were included. Meta-analysis of all study subjects showed no association between PCOS and the PAI-1 4G allele (OR = 0.949, 95% CI = 0.671-1.343, p = 0.767). Stratification by ethnicity, however, indicated a significant association between the PAI-1 4G allele and PCOS in Turkish and Asian populations (OR = 0.776, 95% CI = 0.602-0.999, p = 0.049; OR = 1.749, 95% CI = 1.297-2.359, p = 2.5 × 10-5 respectively). In addition, meta-analysis indicated an association between PCOS and the PAI-1 4G4G + 4G5G genotype in Europeans (OR = 1.406, 95% CI = 1.025-1.928, p = 0.035). However, meta-analysis of all study subjects showed no association between PCOS and the MTHFR 677T allele (OR = 0.998, 95% CI = 0.762-1.307, p = 0.989), including Europeans (OR = 0.806, 95% CI = 0.610-1.063, p = 0.126). Meta-analysis showed no association between PCOS and the MTHFR 677C/T polymorphism using homozygote contrast, and recessive and dominant models. In conclusion, meta-analysis suggests the PAI-1 4G/5G polymorphism is associated with susceptibility to PCOS in European, Turkish, and Asian populations, but the MTHFR 677C/T polymorphism is not associated with susceptibility to PCOS in Europeans.

Original languageEnglish
Pages (from-to)8-14
Number of pages7
JournalEuropean Journal of Obstetrics Gynecology and Reproductive Biology
Volume175
Issue number1
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Methylenetetrahydrofolate Reductase (NADPH2)
Polycystic Ovary Syndrome
Plasminogen Activator Inhibitor 1
Meta-Analysis
Alleles
Homozygote
Population
Genotype

Keywords

  • Meta-analysis
  • MTHFR
  • PAI-1
  • PCOS
  • Polymorphism

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynaecology

Cite this

@article{517e6a694cb8404e94624407cdedc754,
title = "Plasminogen activator inhibitor-1 4G/5G and the MTHFR 677C/T polymorphisms and susceptibility to polycystic ovary syndrome: A meta-analysis",
abstract = "The aim of this study was to explore whether the plasminogen activator inhibitor-1 (PAI-1) 4G/5G and the methylenetetrahydrofolate reductase (MTHFR) 677C/T polymorphisms are associated with susceptibility to polycystic ovary syndrome (PCOS). Meta-analyses were conducted to determine the association between the PAI-1 4G/5G and MTHFR 677C/T polymorphisms and PCOS using: (1) allele contrast (2) homozygote contrast, (3) recessive, and (4) dominant models. For meta-analysis, nine studies of the PAI-1 4G/5G polymorphism with 2384 subjects (PCOS, 1615; controls, 769) and eight studies of the MTHFR 677C/T polymorphism with 1270 study subjects were included. Meta-analysis of all study subjects showed no association between PCOS and the PAI-1 4G allele (OR = 0.949, 95{\%} CI = 0.671-1.343, p = 0.767). Stratification by ethnicity, however, indicated a significant association between the PAI-1 4G allele and PCOS in Turkish and Asian populations (OR = 0.776, 95{\%} CI = 0.602-0.999, p = 0.049; OR = 1.749, 95{\%} CI = 1.297-2.359, p = 2.5 × 10-5 respectively). In addition, meta-analysis indicated an association between PCOS and the PAI-1 4G4G + 4G5G genotype in Europeans (OR = 1.406, 95{\%} CI = 1.025-1.928, p = 0.035). However, meta-analysis of all study subjects showed no association between PCOS and the MTHFR 677T allele (OR = 0.998, 95{\%} CI = 0.762-1.307, p = 0.989), including Europeans (OR = 0.806, 95{\%} CI = 0.610-1.063, p = 0.126). Meta-analysis showed no association between PCOS and the MTHFR 677C/T polymorphism using homozygote contrast, and recessive and dominant models. In conclusion, meta-analysis suggests the PAI-1 4G/5G polymorphism is associated with susceptibility to PCOS in European, Turkish, and Asian populations, but the MTHFR 677C/T polymorphism is not associated with susceptibility to PCOS in Europeans.",
keywords = "Meta-analysis, MTHFR, PAI-1, PCOS, Polymorphism",
author = "Lee, {Young Ho} and Song, {Gwan Gyu}",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.ejogrb.2013.12.030",
language = "English",
volume = "175",
pages = "8--14",
journal = "European Journal of Obstetrics and Gynecology and Reproductive Biology",
issn = "0028-2243",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Plasminogen activator inhibitor-1 4G/5G and the MTHFR 677C/T polymorphisms and susceptibility to polycystic ovary syndrome

T2 - A meta-analysis

AU - Lee, Young Ho

AU - Song, Gwan Gyu

PY - 2014/1/1

Y1 - 2014/1/1

N2 - The aim of this study was to explore whether the plasminogen activator inhibitor-1 (PAI-1) 4G/5G and the methylenetetrahydrofolate reductase (MTHFR) 677C/T polymorphisms are associated with susceptibility to polycystic ovary syndrome (PCOS). Meta-analyses were conducted to determine the association between the PAI-1 4G/5G and MTHFR 677C/T polymorphisms and PCOS using: (1) allele contrast (2) homozygote contrast, (3) recessive, and (4) dominant models. For meta-analysis, nine studies of the PAI-1 4G/5G polymorphism with 2384 subjects (PCOS, 1615; controls, 769) and eight studies of the MTHFR 677C/T polymorphism with 1270 study subjects were included. Meta-analysis of all study subjects showed no association between PCOS and the PAI-1 4G allele (OR = 0.949, 95% CI = 0.671-1.343, p = 0.767). Stratification by ethnicity, however, indicated a significant association between the PAI-1 4G allele and PCOS in Turkish and Asian populations (OR = 0.776, 95% CI = 0.602-0.999, p = 0.049; OR = 1.749, 95% CI = 1.297-2.359, p = 2.5 × 10-5 respectively). In addition, meta-analysis indicated an association between PCOS and the PAI-1 4G4G + 4G5G genotype in Europeans (OR = 1.406, 95% CI = 1.025-1.928, p = 0.035). However, meta-analysis of all study subjects showed no association between PCOS and the MTHFR 677T allele (OR = 0.998, 95% CI = 0.762-1.307, p = 0.989), including Europeans (OR = 0.806, 95% CI = 0.610-1.063, p = 0.126). Meta-analysis showed no association between PCOS and the MTHFR 677C/T polymorphism using homozygote contrast, and recessive and dominant models. In conclusion, meta-analysis suggests the PAI-1 4G/5G polymorphism is associated with susceptibility to PCOS in European, Turkish, and Asian populations, but the MTHFR 677C/T polymorphism is not associated with susceptibility to PCOS in Europeans.

AB - The aim of this study was to explore whether the plasminogen activator inhibitor-1 (PAI-1) 4G/5G and the methylenetetrahydrofolate reductase (MTHFR) 677C/T polymorphisms are associated with susceptibility to polycystic ovary syndrome (PCOS). Meta-analyses were conducted to determine the association between the PAI-1 4G/5G and MTHFR 677C/T polymorphisms and PCOS using: (1) allele contrast (2) homozygote contrast, (3) recessive, and (4) dominant models. For meta-analysis, nine studies of the PAI-1 4G/5G polymorphism with 2384 subjects (PCOS, 1615; controls, 769) and eight studies of the MTHFR 677C/T polymorphism with 1270 study subjects were included. Meta-analysis of all study subjects showed no association between PCOS and the PAI-1 4G allele (OR = 0.949, 95% CI = 0.671-1.343, p = 0.767). Stratification by ethnicity, however, indicated a significant association between the PAI-1 4G allele and PCOS in Turkish and Asian populations (OR = 0.776, 95% CI = 0.602-0.999, p = 0.049; OR = 1.749, 95% CI = 1.297-2.359, p = 2.5 × 10-5 respectively). In addition, meta-analysis indicated an association between PCOS and the PAI-1 4G4G + 4G5G genotype in Europeans (OR = 1.406, 95% CI = 1.025-1.928, p = 0.035). However, meta-analysis of all study subjects showed no association between PCOS and the MTHFR 677T allele (OR = 0.998, 95% CI = 0.762-1.307, p = 0.989), including Europeans (OR = 0.806, 95% CI = 0.610-1.063, p = 0.126). Meta-analysis showed no association between PCOS and the MTHFR 677C/T polymorphism using homozygote contrast, and recessive and dominant models. In conclusion, meta-analysis suggests the PAI-1 4G/5G polymorphism is associated with susceptibility to PCOS in European, Turkish, and Asian populations, but the MTHFR 677C/T polymorphism is not associated with susceptibility to PCOS in Europeans.

KW - Meta-analysis

KW - MTHFR

KW - PAI-1

KW - PCOS

KW - Polymorphism

UR - http://www.scopus.com/inward/record.url?scp=84898059054&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898059054&partnerID=8YFLogxK

U2 - 10.1016/j.ejogrb.2013.12.030

DO - 10.1016/j.ejogrb.2013.12.030

M3 - Review article

VL - 175

SP - 8

EP - 14

JO - European Journal of Obstetrics and Gynecology and Reproductive Biology

JF - European Journal of Obstetrics and Gynecology and Reproductive Biology

SN - 0028-2243

IS - 1

ER -